Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score.
OBJECTIVE
In atrial fibrillation (AF) patients, age >or=75 years is one of the major risk factors for stroke. However, it is not clear if an upper limit for the indication to OAT exists.


RESULTS
For this reason, we performed a prospective study on 290 AF patients on OAT aged >or=75 years (median age 82 years, total follow-up period 814 pt/years) followed by our Anticoagulation Clinic. Seventeen major bleeding events were recorded (rate 2.1 x 100 pt/years), 11 of which cerebral (1.35 x 100 pt/years). The occurrence of major bleedings was associated with history of previous TIA or stroke [OR 3.4 (1.1-12.5), p=0.01] and with diabetes [OR 4.4 (1.3-14.7) p=0.01]. We found a trend to a progressive increase in the rate of bleeding risk with the increase of the CHADS2 score: patients with score 4-6 showed a rate of 3.4 x 100 pt/years with respect to 1.5 x 100 pt/years of patients with lower score. Number Needed to Harm (NNH) was calculated in relation to different classes of age (75-89, 80-84, >or=85 years) and to CHADS2 score. For patients in CHADS2 score 1-3 NNH remained stable across the different age classes. Instead for patients in CHADS2 score 4-6, NNH varied among the 3 groups of ages, reaching a value of 10 in patients >or=85 years.


CONCLUSIONS
Our data suggest that: 1) in AF patients older than 75 years with CHADS2 score 1-3 the risk of bleeding is low, 2) in AF patients >85 years with CHADS2 4-6 the risk of bleeding is high so that the use of OAT should be highly individualised.
Poli
Daniela
D
Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy. polida@aou-careggi.toscana.it
Antonucci
Emilia
E
Marcucci
Rossella
R
Fatini
Cinzia
C
Alterini
Brunetto
B
Mannini
Lucia
L
Falciani
Michela
M
Abbate
Rosanna
R
Gensini
Gian Franco
GF
Prisco
Domenico
D
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D000925:Anticoagulants / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy*; D002543:Cerebral Hemorrhage / Q000209:etiology; D005260:Female; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000150:complications; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors; D020521:Stroke / Q000150:complications; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D014859:Warfarin